Premium
Coadministration of Vascular Disrupting Agents and Nanomedicines to Eradicate Tumors from Peripheral and Central Regions
Author(s) -
Song Wantong,
Tang Zhaohui,
Zhang Dawei,
Yu Haiyang,
Chen Xuesi
Publication year - 2015
Publication title -
small
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.785
H-Index - 236
eISSN - 1613-6829
pISSN - 1613-6810
DOI - 10.1002/smll.201500324
Subject(s) - combretastatin , small molecule , cancer research , nanomedicine , peripheral , tumor cells , nanoparticle , materials science , nanotechnology , pharmacology , medicine , chemistry , microbiology and biotechnology , biology , biochemistry , microtubule , tubulin
A strategy for enhancing the treatment efficacy of nanomedicines within the central region of solid tumors is developed by combining nanomedicines and free small‐molecule vascular disrupting agents (VDAs). The nanomedicines ( cis ‐diamminedichloroplatinum–loaded nanoparticles) primarily target cells at the tumor periphery whereas the free small‐molecule VDA (combretastatin A4 disodium phosphate) efficiently kills the cancer cells within the central regions of the tumor.